WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported...
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.45%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.25%....
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.20%. December E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.33%. December E-mini S&P...
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from...
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621...